The Lancet Diabetes & Endocrinology
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
Randomised trial in 485 peopleInterventions
40 weeks, multicentre, registered NCT06269107
- Insulin icodec + semaglutide
- GLP-1 and incretin signalling
- Insulin/IGF-1 signalling
- Type 2 diabetes
- Blood glucose
- Humans
The paper
Peking University; Universidade Federal do Paraná
The Lancet Diabetes & Endocrinology, 13 Aug 2026
